T-Cell Lymphoma News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

10 Year Cutaneous T-Cell Lymphoma (CTCL) Market Spotlight ... - Business Wire (press release)



10 Year Cutaneous T-Cell Lymphoma (CTCL) Market Spotlight ... 
Business Wire (press release)
This Market Spotlight report covers the Cutaneous T-Cell Lymphoma (CTCL) market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals ...

and more » 


Corvus Pharmaceuticals Announces Presentation of New Data from Preclinical Study of Novel T-Cell Signaling ... - GlobeNewswire (press release)



Corvus Pharmaceuticals Announces Presentation of New Data from Preclinical Study of Novel T-Cell Signaling ... 
GlobeNewswire (press release)
BURLINGAME, Calif., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced new ...
CORVUS PHARMACEUTICALS, INC. (NASDAQ:CRVS) Files An 8-K Other Events Market Exclusive

all 7 news articles » 


With Approval of CAR T-Cell Therapy Comes the Next Challenge ... - AJMC.com Managed Markets Network



With Approval of CAR T-Cell Therapy Comes the Next Challenge ... 
AJMC.com Managed Markets Network
CAR T- cell therapies are among the most expensive ever invented. For now, there's a lot of uncertainty, as both government and commercial insurers, and a handful of the nation's leading cancer centers, navigate a reimbursement structure that truly has ...
Undervalued And Attractive: Pick Up Novartis In 2018 - Novartis AG ... Seeking Alpha

all 2 news articles » 


Comparing CAR T-Cell Therapies in Lymphoma - Medscape



Medscape
 
Comparing CAR T-Cell Therapies in Lymphoma 
Medscape
Ann S. LaCasce, MD, MMSc: Hello. I am Ann LaCasce, an associate professor of medicine at Dana-Farber Cancer Institute in Boston and a lymphoma specialist. I would like to welcome you to Medscape Oncology Insights, coming to you from the 2017 American ...

 


miRagen Therapeutics to Present New MRG-106 Phase 1 Clinical Trial Data at the T-Cell Lymphoma Forum - GlobeNewswire (press release)



GlobeNewswire (press release)
 
miRagen Therapeutics to Present New MRG-106 Phase 1 Clinical Trial Data at the T-Cell Lymphoma Forum 
GlobeNewswire (press release)
BOULDER, Colo., Jan. 24, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that new interim results from its ...

and more » 


Axi-Cel and Future of CAR T-Cell Therapy in Lymphoma - OncLive



OncLive
 
Axi-Cel and Future of CAR T-Cell Therapy in Lymphoma 
OncLive
So, I think this is particularly an exciting time to be in the field of lymphoma research or hematological cancer research with these exciting developments with CAR T-cell therapy. I think this gives a lot more hope to the patients who die from this ...

and more » 


'Encouraging' results with JCAR017 for relapsed, refractory lymphoma - Healio



'Encouraging' results with JCAR017 for relapsed, refractory lymphoma 
Healio
High-risk patients with relapsed and refractory diffuse large B-cell lymphoma who received JCAR17 chimeric antigen receptor T-cell therapy had an overall response rate of 80% and a complete remission rate of 55%, according to results of a phase 1 trial ...

 


ICER Report: Costs of Approved CAR T-Cell Therapies Aligned With Clinical Benefit - AJMC.com Managed Markets Network



ICER Report: Costs of Approved CAR T-Cell Therapies Aligned With Clinical Benefit 
AJMC.com Managed Markets Network
... and older with relapsed/refractory B-cell lymphoma who were ineligible for auto-stem cell transplant, the report compared the CAR T therapies with chemotherapy. The average sales price for chemotherapy treatments were used, while the wholesale ...

 


ACVP 2017: Overview of Ferret Lymphoma - American Veterinarian



American Veterinarian
 
ACVP 2017: Overview of Ferret Lymphoma 
American Veterinarian
In his presentation at the 2017 annual meeting of the American College of Veterinary Pathologists (ACVP) in Vancouver, British Columbia, Canada, Dr. Williams reviewed some important aspects of the different variants of lymphoma in ferrets. There is no ...

 


Study results may lead to 'completely different way' of treating lymphoma subtype - Healio



Study results may lead to 'completely different way' of treating lymphoma subtype 
Healio
ATLANTA ? Results from the updated ZUMA-1 trial indicate that CAR T-cell therapies are effective for various cancers that have not yet received FDA approval, according to Gwen Nichols, MD, chief medical officer of the Leukemia & Lymphoma Society ...